IASLC World Conference on Lung Cancer

Tagrisso Combination Improves Survival in EGFR-Mutant NSCLC

October 6th 2025, 8:00pm

Video

In EGFR-mutated non-small cell lung cancer Tagrisso with pemetrexed and chemotherapy was associated with an improvement in survival.

Understanding the Evolving Role of a Pathologist in Lung Cancer Care

October 1st 2025, 1:00pm

Video

Dr. Mary B. Beasley discusses evolving role of pathologists in lung cancer care, highlighting how emerging technologies may shape the future of the field.

Ibtrozi Emerging as New Standard for ROS1-Mutated Lung Cancer

September 26th 2025, 8:00pm

Video

Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients.

Understanding Lung Cancer Trial Results and Their Treatment Impact

September 25th 2025, 8:00pm

Video

Dr. Jacob A. Sands shares how patients with lung cancer can interpret clinical trial results and how these findings translate to treatment decisions.

Understanding the Importance of Biomarker Testing in Lung Cancer

September 16th 2025, 8:00pm

Video

Dr. Joshua K. Sabari sat down with Terri Conneran at the 2025 World Conference on Lung Cancer for a conversation on the importance of biomarker testing.

Patient Advocate and Caregiver Shares Advocacy Journey in KRAS Cancers

September 15th 2025, 1:00pm

Video

Dr. Joshua Sabari spoke with advocate Chris Conneran on his journey from caregiver to champion for KRAS-mutant cancer patients and families.

Real-World Study Finds Benefit of Lutathera in Patients With Lung NETs

September 14th 2025, 2:00pm

Article

Lutathera demonstrated antitumor activity in patients with metastatic bronchopulmonary neuroendocrine tumors.

Tepmetko Associated With Frequent Side Effects for Some With NSCLC

September 13th 2025, 6:00pm

Article

For patients with MET exon 14-altered NSCLC, Tepmetko was associated with frequent side effects, although the safety profile is considered manageable.

Using AI to Improve Clinical Trial Access for Those With Lung Cancer

September 12th 2025, 8:00pm

Video

Dr. Josh Sabari and Max Doppelt explore challenges in trial enrollment and the potential of emerging therapies to offer hope for patients diagnosed today.

THIO Plus Libtayo Elicits Positive Responses in Advanced NSCLC

September 12th 2025, 3:00pm

Article

For patients with advanced non-small cell lung cancer who progressed on two or more prior regimens, THIO with Libtayo elicited positive responses.